Welcome to our dedicated page for Glycomimetics news (Ticker: GLYC), a resource for investors and traders seeking the latest updates and insights on Glycomimetics stock.
Glycomimetics Inc. (GLYC) is a clinical-stage biotechnology company pioneering glycomimetic drug development for diseases with high unmet medical needs, including sickle cell disease and cancer. This page serves as the definitive source for verified corporate news, research milestones, and regulatory developments.
Investors and industry observers will find timely updates on clinical trial progress, partnership announcements, and financial results. Our curated collection ensures access to all material disclosures, including analysis of scientific advancements within the company’s unique glycobiology platform.
Key updates cover phase trial results, regulatory submissions, collaborative research initiatives, and strategic business developments. Content is rigorously verified to provide accurate context for understanding the company’s position in the competitive biotech landscape.
Bookmark this page for streamlined tracking of Glycomimetics’ progress in advancing its pipeline of novel therapeutics. Check regularly for essential updates that could inform long-term evaluation of this innovative biopharmaceutical enterprise.
GlycoMimetics, Inc. (NASDAQ:GLYC) announced the grant of a non-qualified stock option for 200,000 shares to Dr. Edwin P. Rock, the new Senior VP and Chief Medical Officer, on September 2, 2022. This award, which has an exercise price of $0.74 per share, is part of an inducement equity package outside their equity incentive plan. Vesting occurs with 25% on September 2, 2023, followed by equal monthly installments over 36 months. GlycoMimetics focuses on developing glycobiology-based therapies for cancers and inflammatory diseases.
GlycoMimetics, Inc. (Nasdaq: GLYC) announced that CEO Harout Semerjian will present at the H.C. Wainwright 24th Annual Global Investment Conference in New York, NY on September 14, 2022, at 3:00 p.m. ET. An archived recording of the presentation will be accessible for 90 days on GlycoMimetics' website.
The company specializes in developing glycobiology-based therapies for cancers like acute myeloid leukemia (AML), aiming to create transformative treatments through its proprietary platform.
GlycoMimetics, Inc. (NASDAQ: GLYC) has appointed Edwin Rock, M.D., Ph.D., as the new Chief Medical Officer. Dr. Rock brings nearly two decades of biopharmaceutical experience, having previously served as CMO at Partner Therapeutics. He has expertise in clinical development and regulatory functions for therapies aimed at hematologic malignancies. This addition is expected to enhance GlycoMimetics' leadership as it prepares for pivotal Phase 3 data readout of its investigational drug, uproleselan, in acute myeloid leukemia (AML), which has already received Breakthrough Therapy designation from the FDA.
GlycoMimetics (Nasdaq: GLYC) received FDA clearance for its IND application to study GMI-1687 for sickle cell disease. The company is advancing its pivotal Phase 3 trial for uproleselan in relapsed/refractory acute myeloid leukemia (AML), anticipating survival data by mid-2023. As of June 30, 2022, GlycoMimetics reported cash and equivalents of $60.2 million, down from $90.3 million at year-end 2021. R&D expenses decreased to $8.0 million while G&A expenses rose to $5.5 million. A conference call is scheduled for today at 8:30 a.m. ET to discuss these developments.
GlycoMimetics, Inc. (GLYC) announced a conference call on August 3, 2022, at 8:30 a.m. ET, to discuss its second quarter financial results. Investors can participate via a registration link provided in the announcement or access a live webcast through the company’s website. GlycoMimetics is focused on developing glycobiology-based therapies for cancers like acute myeloid leukemia and inflammatory diseases. The company aims to advance its drug candidates to address significant healthcare needs.
GlycoMimetics, Inc. (NASDAQ: GLYC) will participate in the Jefferies 2022 Healthcare Conference on June 8 in New York, NY. CEO Harout Semerjian and CFO Brian Hahn will attend, with a fireside chat hosted by Research Analyst Roger Song, M.D. The chat will be available for 30 days on the GlycoMimetics website starting June 8 at approximately 3:30 p.m. ET. GlycoMimetics is a clinical-stage biotechnology company focused on developing glycobiology-based therapies for cancers and inflammatory diseases, aiming to create transformative treatments.
GlycoMimetics (NASDAQ: GLYC) reported its financial results for Q1 2022, with cash and equivalents at $76.5 million, down from $90.3 million at the end of 2021. The company recorded no revenue for the quarter compared to $1.1 million in Q1 2021. Research and development expenses decreased to $9.6 million, while general and administrative expenses rose to $5.1 million. The company is on track for key events in its clinical trials, including the pivotal Phase 3 trial for uproleselan in relapsed/refractory AML anticipated in mid-2023.
GlycoMimetics, Inc. (Nasdaq: GLYC) will host a conference call and webcast on
GlycoMimetics, Inc. (Nasdaq: GLYC) will participate in the 34th Annual Roth Conference on March 14-15 in Laguna Niguel, California. CEO Harout Semerjian and CFO Brian Hahn will attend, with a fireside chat hosted by Research Analyst Zegbeh Jallah. An archived recording will be available on the GlycoMimetics website starting March 15 at approximately 2:00 p.m. PST. The company focuses on developing glycobiology-based therapies for cancers and inflammatory diseases. For more information, visit www.glycomimetics.com.
GlycoMimetics, Inc. (NASDAQ:GLYC) announced the grant of a stock option award on March 1, 2022, for 100,000 shares to Deepak Tiwari, its new Vice President of Technical Operations. This award, approved by the compensation committee, is a non-qualified stock option granted outside the 2013 Equity Incentive Plan, complying with NASDAQ Listing Rule 5635(c)(4). The options vest 25% on March 1, 2023, with the remainder vesting monthly over three years. The exercise price is set at $1.27 per share, equal to the closing stock price on the grant date.
FAQ
What is the current stock price of Glycomimetics (GLYC)?
What is the market cap of Glycomimetics (GLYC)?
